BoFA says Novo Nordisk may miss Q1 expectations as Wegovy, Ozempic sales lag
Bank of America analysts on Friday said Novo Nordisk may miss first-quarter expectations, as sales of its blockbuster Wegovy ...
Novo Nordisk says copycat compounders are hurting Wegovy sales, may take legal action
Novo Nordisk said Thursday that the rampant growth of the U.S.’ compounded drug industry was hurting Wegovy sales, and warned ...
Lexicon Pharmaceuticals, Novo Nordisk strike obesity-drug license deal worth up to $1B
Lexicon Pharmaceuticals Inc. said March 28 it will exclusively license its drug candidate LX9851 to Danish pharmaceutical ...
STAT1d
Novo Nordisk sets sights on new type of oral obesity drug
Novo Nordisk has licensed an oral obesity drug that works via an uncommon mechanism and may help patients maintain their ...
Novo Nordisk's next-gen obesity drug CagriSema had investors excited. Now they're not so sure
Novo Nordisk’s hopes of heralding a new era of obesity treatment with its next-generation CagriSema drug may be in doubt ...
Is Novo Nordisk Stock a Buy?
Novo Nordisk leads a GLP-1 agonist market that could surpass $150 billion by 2035. Ironically, the market is passing on the ...
Novo says Ozempic succeeded in late-stage trial for peripheral artery disease
Novo Nordisk (NVO) says its obesity drug Ozempic improved walking distance for diabetes patients with peripheral artery ...
Lexicon's Drug Discovery Engine Validated By Novo's $1 Billion Obesity Drug Deal (Upgrade)
Lexicon's stock rose 60% after securing a potential $1 billion deal with Novo Nordisk for preclinical obesity drug LX9851.
GlobalData on MSN1d
Novo Nordisk strikes $1bn deal for Lexicon’s oral obesity drug
Novo Nordisk has signed a deal worth up to $1bn with Lexicon Pharmaceuticals for the exclusive global rights to LX9851, an ...